Astec LifeSciences Limited — Important, 04-07-2025: General Updates

Astec LifeSciences has announced a board meeting on 28th July, 2025, to approve the financial results for the quarter and half-year. The company reported a challenging FY25 with total income down to ₹386.93 Cr from ₹463.82 Cr, and a loss after tax widening to ₹134.71 Cr from ₹46.89 Cr last year. Export sales dropped 21%, domestic sales fell 8%, and CDMO sales contribution declined from 60% to 54%. Gross margin compressed to 22.1% from 30.3%. Despite short-term pressures, emphasis remains on scaling the CDMO segment, leveraging the advanced Adi Godrej R&D Center, and focusing on operational efficiencies to drive medium-term growth. Related party transactions with Godrej Agrovet are approved up to ₹400 Cr for FY26.